Indication :
- The drug is a cytostatically active antibiotic of the anthracycline group. These substances suppress cell division and cause disturbances in cellular metabolism, which ultimately leads to the death of the tumor cell.
- It is indicated to initiate tumor regression (induce remission) as a component of oral attenuated combination therapy (eg, etoposide, thioguanine) in elderly, treatment-naïve patients with acute myeloid leukemia (AML, ANLL).  ;However, intravenous chemotherapy is the first choice therapy in the treatment of AML, allowing to initiate tumor regression (induction of remission).
- The drug should not be used solely for disease relief (palliative) treatment of AML.
- It is intended only for use under the guidance of physicians experienced in the treatment of leukemia.
Dosage :
- Treatment should only be carried out by doctors experienced in treating leukemia, in a clinic or in collaboration with a clinic.
- Always take this medication exactly as your doctor told you. If you are not sure, ask your doctor or pharmacist.
- Adult
- As a rule, the dosage is calculated based on body surface area.
- The number of capsules taken is determined by the doctor individually. In combination therapy, the following dosage is recommended:
- 15–30 mg idarubicin hydrochloride/m² body surface daily for 3 days. It is necessary to take into account the individual condition of the particular patient and the dosage of simultaneously administered cell-damaging substances.
- Children and young people
- There are no data on use in patients under 18 years of age. Therefore, use in children and adolescents is not recommended.
- Patients with liver and/or kidney dysfunction.
- Tell your doctor if you have liver and/or kidney problems. If necessary, your doctor may initiate a dose reduction or discontinuation of the drug.
